Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 61 to 70 of 2442 total matches.
Tretinoin/Benzoyl Peroxide Cream (Twyneo) for Acne
The Medical Letter on Drugs and Therapeutics • May 16, 2022 (Issue 1650)
trials included applicationsite
pain (10.6%), dryness (4.9%), exfoliation (4.1%),
erythema (4.0 ...
The FDA has approved Twyneo (Galderma), a cream
containing the retinoid tretinoin and the oxidizing
agent benzoyl peroxide, for once-daily topical
treatment of acne in patients ≥9 years old.
Cefiderocol (Fetroja) - A New IV Cephalosporin for Complicated UTI
The Medical Letter on Drugs and Therapeutics • May 04, 2020 (Issue 1597)
a cephalosporin or a carbapenem with
a beta-lactamase inhibitor such as ceftazidime/
avibactam (Avycaz),1 ...
The FDA has approved cefiderocol (Fetroja – Shionogi),
a new IV cephalosporin antibiotic, for treatment of
complicated urinary tract infections (UTI) caused by
susceptible gram-negative bacteria in adults who
have limited or no alternative treatment options.
Antibacterial Prophylaxis for Dental, GI and GU Procedures
The Medical Letter on Drugs and Therapeutics • Jul 18, 2005 (Issue 1213)
practice has
never been established by controlled trials in humans.
1
The drugs and dosages in the table ...
Many physicians believe that antimicrobial prophylaxis before procedures that may cause transient bacteremia can prevent endocarditis and prosthetic joint infection in patients at increased risk for these disorders. The effectiveness of this common practice has never been established by controlled trials in humans.
Trifarotene (Aklief) - A New Topical Retinoid for Acne
The Medical Letter on Drugs and Therapeutics • Dec 16, 2019 (Issue 1587)
by
prescription for decades. Adapalene 0.1% gel has been
available over the counter since 2016 for treatment ...
The FDA has approved trifarotene 0.005% cream
(Aklief – Galderma) for topical treatment of acne
vulgaris in patients ≥9 years old. Trifarotene is the
fourth topical retinoid to be approved in the US for
treatment of acne; tretinoin (Retin-A, and others),
adapalene (Differin, and generics), and tazarotene
(Tazorac, and others) have been available by
prescription for decades. Adapalene 0.1% gel has been
available over the counter since 2016 for treatment of
acne in patients ≥12 years old.
Nivolumab (Opdivo) for Metastatic Melanoma and Metastatic NSCLC
The Medical Letter on Drugs and Therapeutics • Jun 08, 2015 (Issue 1470)
death receptor-1 (PD-1) blocking
antibody, for treatment of unresectable or metastatic
melanoma ...
The FDA has approved nivolumab (Opdivo – BMS),
an IV programmed death receptor-1 (PD-1) blocking
antibody, for treatment of unresectable or metastatic
melanoma that has progressed following treatment
with ipilimumab (and a BRAF inhibitor in patients who
are BRAF V600 mutation positive) and for treatment
of metastatic squamous non-small cell lung cancer
(NSCLC) that has progressed on or after platinum-based
chemotherapy. It is the second PD-1 inhibitor to
be marketed in the US after pembrolizumab (Keytruda),
and the first to be approved for treatment of NSCLC.
Oat Bran for Lowering Blood Lipids
The Medical Letter on Drugs and Therapeutics • Dec 02, 1988 (Issue 780)
effect than insoluble fiber (IM
Ullrich, J Am Coll Nutr, 1:19, 1987). The mechanism of action ...
Oat bran, the ground inner husk of the grain, has recently become popular as a dietary means of lowering blood lipids. It is available both separately and as a constituent of oatmeal, which is the ground product of the whole grain. Oat bran and oatmeal are available in various breakfast cereals and can also be used in baked goods, such as muffins or bread. Some of these sources are listed in the table on page 112.
Minocycline Foam (Zilxi) for Rosacea
The Medical Letter on Drugs and Therapeutics • Nov 16, 2020 (Issue 1611)
Minocycline Foam (Zilxi) for Rosacea
The FDA has approved a 1.5% topical foam formulation ...
The FDA has approved a 1.5% topical foam formulation
of minocycline (Zilxi – Foamix) for treatment of
inflammatory lesions of rosacea in adults. It is
the only topical minocycline product approved for
this indication. The same manufacturer markets
minocycline foam 4% (Amzeeq) for treatment of acne
in patients ≥9 years old.
Semaglutide (Ozempic) for Weight Loss
The Medical Letter on Drugs and Therapeutics • Apr 05, 2021 (Issue 1621)
subcutaneous injection of the glucagon-like peptide 1
(GLP-1) receptor agonist semaglutide (Ozempic –
Novo ...
In recently published clinical trials, once-weekly
subcutaneous injection of the glucagon-like peptide 1
(GLP-1) receptor agonist semaglutide (Ozempic – Novo Nordisk), which is FDA-approved for treatment of
type 2 diabetes and to reduce the risk of major adverse
cardiovascular events in adults with type 2 diabetes
and established cardiovascular disease, has reduced
body weight significantly in patients with and without
type 2 diabetes when given in addition to lifestyle
intervention. Liraglutide (Saxenda), another GLP-1
receptor agonist, has been FDA-approved for chronic
weight...
In Brief: Finerenone (Kerendia) for Diabetic Kidney Disease
The Medical Letter on Drugs and Therapeutics • Jan 23, 2023 (Issue 1668)
(CKD).1,2
FINERENONE — Finerenone was approved by
the FDA in 2021 to reduce the risk of sustained ...
Recently published guidelines from the American
Diabetes Association (ADA) and the Kidney Disease:
Improving Global Outcomes (KDIGO) Diabetes Work
Group recommend addition of the oral nonsteroidal
mineralocorticoid receptor antagonist (MRA)
finerenone (Kerendia) to standard treatment in
patients with type 2 diabetes and chronic kidney
disease (CKD).
Med Lett Drugs Ther. 2023 Jan 23;65(1668):15-6 doi:10.58347/tml.2023.1668e | Show Introduction Hide Introduction
Two New Drugs for Glaucoma
The Medical Letter on Drugs and Therapeutics • Jul 16, 2018 (Issue 1551)
effective and may be better tolerated. The
0.1% formulation of the drug is better tolerated than
higher ...
The FDA has approved two new ophthalmic drugs for
reduction of intraocular pressure (IOP) in patients with
open-angle glaucoma or ocular hypertension: latanoprostene
bunod (Vyzulta – Bausch and Lomb), a modified
prostaglandin analog, and netarsudil (VRhopressa – Aerie),
the first Rho kinase inhibitor to be approved in the US.